Neuste News
- Amgen, Cytokinetics und Servier geben Topline-Ergebnisse von Galactic-HF bekannt, einer Phase-3-Studie mit Omecamtiv-Mecarbil bei Patienten mit Herzinsuffizienz
- Great Place to Work - Switzerland
- Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
- ISHR-ES – Servier Research Fellowship 2017 awarded to Dr Vasco Sequeira Oliveira
- Servier licenses GLPG1972 in osteoarthritis from Galapagos
- Servier announces an increase in turnover for 2015-2016
- Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
- Servier is the first French pharmaceutical company to partner with Plug and Play Health & Wellness
- Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership.
- Servier and ILTOO Pharma sign a license option agreement for the clinical development and commercialization of low-dose interleukin-2 for the treatment of autoimmune diseases
- Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
- Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration
- Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
- Biogaran takes over Swipha’s activities in Nigeria to produce generic drugs for the local market
- Dr Claude BERTRAND, General Director of Research and Development at Servier
